

STATEMENT SHOWING PRILIMINARY TECHNICAL EVALUATION FOR T NO 161 (GENERAL MEDICINES)					
S No	Bidder Name	Item Code	Item Name	Item Remarks	Status
1	<b>9M INDIA LIMITED</b>	<b>Technical Evaluation Remarks by DGDCA:</b> The firm may be considered with S.No. 1, 2, 3, 5, 6, 7, 8, 9, 10, 12 & 13 products and May be considered for S.No. 4 & 11 after submission of valid product approval			
		1693	Atropine Sulphate Injection IP 0.6 mg /ml		May be considered
		1741	Baclofen Tablet IP 10mg		May be considered
		69	Betamethasone Sodium Phosphate Injection IP 4mg/ml in 1 ml amp		May be considered
		123	Ciprofloxacin Hcl Eye /Ear Drops IP 0.3 percentage w/v in 5 ml	Valid product approval was not submitted May be considered after submission of valid product approval	May not be considered
		221.02	Dexamethasone Injection IP 8 mg / 2ml		May be considered
		2462	Diclofenac Sodium Injection Aqueous Base 75 mg/ 1 ml		May be considered
		745	Haloperidol Injection IP 5 mg / 1ml		May be considered
		1308	Losartan Potassium Tablets IP 50 mg (film coated)		May be considered
		1640	Methyl Cobalamin Injection 500mcg in 1 ml		May be considered
		4036	Metronidazole ointment/Gel (1.5percentage w/w of metronidazole 20 gm for oral use)		May be considered
		1904	Olanzapine Tablets 10mg	Enclosed drug license for Mouth dissolving tablets Not enclosed valid drug license May be considered after submission of relavent document	May not be considered
		607	Ranitidine Hcl Injection IP 25 mg / ml in 2ml amp		May be considered
		4046	Vitamin D 60k		May be considered
2	<b>Biodeal Pharmaceuticals Limited</b>	<b>Technical Evaluation Remarks by DGDCA:</b> The firm may be considered after submission of EMD fee The firm may be considered with S.No. 2 product and May be considered for S.No. 1 after submission of valid product license			
		1904	Olanzapine Tablets 10mg	Submitted approval product list for Mouth disloving tablets May be considered after submission of valid product license	May not be considered

S No	Bidder Name	Item Code	Item Name	Item Remarks	Status
		2135	Rosuvastatin Calcium 10 mg Tablet(Additional Indication)		May be considered
3	<b>BRIYOSIS SOFT CAPS PRIVATE LIMITED</b>	<b>Technical Evaluation Remarks by DGDCA:</b> The firm submitted documents are in order and satisfactory, Hence the firm may be considered			
		4046	Vitamin D 60k		May be considered
4	<b>CIPCO PHARMACEUTICALS</b>	<b>Technical Evaluation Remarks by DGDCA:</b> Considered for S.No. 1, 2, 3 products, Firm May be considered			
		24012402	Hydrochlorthiazide 12.5 mg Tablets		May be considered
		1308	Losartan Potassium Tablets IP 50 mg (film coated)		May be considered
		2135	Rosuvastatin Calcium 10 mg Tablet(Additional Indication)		May be considered
5	<b>CIPLA LTD</b>	<b>Technical Evaluation Remarks by DGDCA:</b> Considered products S.No. 1, 2, 4, 5, 8, 9, 10 and the remain products may be considered after submission of For S.No.3 - Product approval copy, GMP certificate & NCC certificate For S.No.7 - GMP certificate For S.No.6 & 11 - Strength is not tallied All the documents are in order and satisfactory, Hence the firm may be considered			
		1695	Amiodarone Hcl Tablets IP 100 mg		May be considered
		123	Ciprofloxacin Hcl Eye /Ear Drops IP 0.3 percentage w/v in 5 ml		May be considered
		23012406	Fluticasone 100mcg	Not produced product approval copy May be considered after submission of product approval, NCC & GMP	May not be considered
		23012416	Levosambutamol plus Ipratropium 0.63 plus 500mcg		May be considered
		23012415	Levosambutamol plus Ipratropium 1.25 plus 500mcg		May be considered
		23012412	Levosambutamol respule 0.32 mg	Strength is not tallied	May not be considered
		23012411	Levosambutamol respule 0.63 mg	Cipla ltd at Aculife, virmgam G/25A/4564-A valid upto 03/01/2026, NCC dt:27/10/23 May be considered after submission of GMP certificate	May not be considered

S No	Bidder Name	Item Code	Item Name	Item Remarks	Status
		23012413	Levosalbutamol respule 1.25 mg		May be considered
		543	Propranolol Hcl Tablets IP 40 mg		May be considered
		2135	Rosuvastatin Calcium 10 mg Tablet(Additional Indication)		May be considered
		23012401	Tiotropium 18mcg	Strength of drug is not tallied	May not be considered
6	CMG BIOTECH PVT LTD	<b>Technical Evaluation Remarks by DGDCA:</b> Considered products S.No. 1, 2, 4, 5, 6, 9 other remaining products S.No. 3, 7, 8, 10, 11, 12 May be considered on submission of relevant product licenses w.r.t Coating and Domestic supply			
		1695	Amiodarone Hcl Tablets IP 100 mg		May be considered
		1741	Baclofen Tablet IP 10mg		May be considered
		13122318	Calcium Polystyrene Sulphonate powder 15G Sachet	Submitted Export permission, Not submitted Domestic approval May be considered on submission of domestic supply approval	May not be considered
		2485	Clonidine Tab 100mcg		May be considered
		24012402	Hydrochlorthiazide 12.5 mg Tablets		May be considered
		1308	Losartan Potassium Tablets IP 50 mg (film coated)		May be considered
		1904	Olanzapine Tablets 10mg	Specification is not matching (submitted film coated apporval) pg:44 May be considered on submission of uncoated approval	May not be considered
		2369	Olmесartan Medoxomil Tablets 40mg	Specification is not matching (submitted film coated apporval) pg:26 May be considered on submission of uncoated approval	May not be considered
		543	Propranolol Hcl Tablets IP 40 mg		May be considered
		1929	Quitiapine Tab 100mg	Specification is not matching (submitted film coated apporval) pg:31 May be considered on submission of uncoated approval	May not be considered

S No	Bidder Name	Item Code	Item Name	Item Remarks	Status
		2135	Rosuvastatin Calcium 10 mg Tablet(Additional Indication)	Specification is not matching (submitted film coated apporval) pg:38 May be considered on submission of uncoated approval	May not be considered
		2161	Topiramate Tab 50mg	Specification is not matching (submitted film coated apporval) pg:32 May be considered on submission of uncoated approval	May not be considered
7	<b>Eurokem Laboratories Pvt Ltd.</b>	<b>Technical Evaluation Remarks by DGDCA:</b> Firm not submitted valid license of the product item no 1 and 3. Firm not submitted valid product license of the specified item no 2 and 4 w.r.t coating Item no 1, 2, 3, 4 May be considered on submission of the relevant product approvals			
		1308	Losartan Potassium Tablets IP 50 mg (film coated)	Submitted product approval valid upto 31/12/2021 pg-13 May be considered on submission of valid product license	May not be considered
		1904	Olanzapine Tablets 10mg	Submittd product approval of film coated tablet valid upto 31-12-2021, Need valid product license of uncoated tablets pg-12 May be considered on submission of valid product license	May not be considered
		543	Propranolol Hcl Tablets IP 40 mg	Submitted product approval valid upto 31/12/2021 pg-11, Not submitted valid product license May be considered on submission of valid product license	May not be considered
		605	Ranitidine Hcl (Film Coated) Tablets IP 150 mg	Submitted product license for coated tablet, need license for film coated tablet pg-11 May be considered on submission of clarification w.r.t coating or necessary product approval	May not be considered
8	<b>FREDUN PHARMACEUTICALS LIMITED</b>	<b>Technical Evaluation Remarks by DGDCA:</b> Products at S.No. 1 & 2 May be considered			
		1308	Losartan Potassium Tablets IP 50 mg (film coated)		May be considered
		2135	Rosuvastatin Calcium 10 mg Tablet(Additional Indication)		May be considered
9	<b>FRESENIUS KABI ONCOLOGY LIMITED</b>	<b>Technical Evaluation Remarks by DGDCA:</b> May be considered only after submission of the valid license/document			

S No	Bidder Name	Item Code	Item Name	Item Remarks	Status
		2276	Paclitaxel USP-100mg Nano particle polymer-based	Specification didn't math with the requirement (Instead of 20ml of reconstituted solution, the product contains 5ml solution for reconstitution)	May not be considered
10	J B CHEMICALS & PHARMACEUTICALS LTD	<b>Technical Evaluation Remarks by DGDC:</b> May not be considered for S.No. 1 & 2			
		605	Ranitidine Hcl (Film Coated) Tablets IP 150 mg	The applicant submitted product approval for efferuscent tablets, specifications not matched	May not be considered
		2135	Rosuvastatin Calcium 10 mg Tablet(Additional Indication)	The applicant submitted product approval for film coated tablets, specifications not matched	May not be considered
11	KONIS PHARMACEUTICALS	<b>Technical Evaluation Remarks by DGDC:</b> The firm may be considered after submission of valid Non Conviction Certificate			
		1693	Atropine Sulphate Injection IP 0.6 mg /ml	Valid license submitted	May be considered
		123	Ciprofloxacin Hcl Eye /Ear Drops IP 0.3 percentage w/v in 5 ml	Valid license submitted	May be considered
		221.02	Dexamethasone Injection IP 8 mg / 2ml	Valid license submitted	May be considered
		2462	Diclofenac Sodium Injection Aqueous Base 75 mg/ 1 ml	Valid license submitted	May be considered
		1125	Hyoscine Butyl Bromide Injection IP 20 mg / ml 1 amp	Valid license submitted	May be considered
		607	Ranitidine Hcl Injection IP 25 mg / ml in 2ml amp	Valid license submitted	May be considered
12	LUPIN LIMITED	<b>Technical Evaluation Remarks by DGDC:</b> The firm may be considered for product S.No. 1			
		2276	Paclitaxel USP-100mg Nano particle polymer-based		May be considered
13	Mankind Pharma Limited	<b>Technical Evaluation Remarks by DGDC:</b> All the required documents are in order, Hence May be considered for all the products 1, 2 & 3.			
		1308	Losartan Potassium Tablets IP 50 mg (film coated)		May be considered
		1640	Methyl Cobalamin Injection 500mcg in 1 ml		May be considered

S No	Bidder Name	Item Code	Item Name	Item Remarks	Status
		2369	Olmesartan Medoxomil Tablets 40mg		May be considered
14	SEEKO BIOTICS	<b>Technical Evaluation Remarks by DGDCA:</b> The firm may be considered for product S.No. 1 to 7			
		2064	Amitriptyline Tablets IP 10mg		May be considered
		1308	Losartan Potassium Tablets IP 50 mg (film coated)		May be considered
		1904	Olanzapine Tablets 10mg		May be considered
		543	Propranolol Hcl Tablets IP 40 mg		May be considered
		1929	Quitiaipine Tab 100mg		May be considered
		605	Ranitidine Hcl (Film Coated) Tablets IP 150 mg		May be considered
		1325	Serrapeptidase tablets IP 10mg		May be considered
15	STRIDE ORGANICS PVT LTD	<b>Technical Evaluation Remarks by DGDCA:</b> Considered for S.No. 3, 5 & 7. May be considered after submission of correct specifications of S.No. 1, 2, 4 & 6			
		1308	Losartan Potassium Tablets IP 50 mg (film coated)	The applicant submitted product approval for uncoated tablets, Specifications not matched	May not be considered
		1644	Multivitamins Tablets (Therapeutic)	The applicant submitted product approval for film coated tablets, specifications not matched	May not be considered
		1902	Ofloxacin Tablets 100mg		May be considered
		1904	Olanzapine Tablets 10mg	Submitted product approval as film coated specifications not matched	May not be considered
		605	Ranitidine Hcl (Film Coated) Tablets IP 150 mg		May be considered
		1325	Serrapeptidase tablets IP 10mg	Submitted product approval as Enteric coated specifications not matched	May not be considered
		4046	Vitamin D 60k		May be considered
16	TAS MED (INDIA) PRIVATE LIMITED	<b>Technical Evaluation Remarks by DGDCA:</b> All Product items S.No. 1 to 6 May be considered			
		2064	Amitriptyline Tablets IP 10mg		May be considered
		746	Haloperidol Tablets IP 5mg		May be considered
		1308	Losartan Potassium Tablets IP 50 mg (film coated)		May be considered

S No	Bidder Name	Item Code	Item Name	Item Remarks	Status
		1904	Olanzapine Tablets 10mg		May be considered
		2369	Olmesartan Medoxomil Tablets 40mg		May be considered
		2135	Rosuvastatin Calcium 10 mg Tablet(Additional Indication)		May be considered
17	Vee Excel Drugs and Pharmaceuticals Private Ltd	<b>Technical Evaluation Remarks by DGDCA:</b> The applied products 1, 2, 3, 4 May be considered after submission of valid product mfg licenses			
		2064	Amitriptyline Tablets IP 10mg	Produced product license dt: 11/04/2022 (pg:17) but not produced valid product license	May not be considered
		1904	Olanzapine Tablets 10mg	Produced product license dt: 04/03/2021 (pg:18) but not produced valid product license	May not be considered
		605	Ranitidine Hcl (Film Coated) Tablets IP 150 mg	Produced product license dt: 04/03/2022 (pg:18) but not produced valid product license	May not be considered
		1325	Serrapeptidase tablets IP 10mg	Produced product license dt: 28/08/2020 (pg:17) but not produced valid product license	May not be considered
<p><b>Note: All the bidders are hereby requested to verify the Provisional Technical Evaluation Report and submit their supporting documents on or before 05.00PM on 12.07.2024 to the email id: <a href="mailto:tenders.apmsidc@gmail.com">tenders.apmsidc@gmail.com</a> with Subject : Reply to T No 161 (General Medicines) TEC Report</b></p>					